A study of novel agents or combinations as perioperative treatment in participants with locally advanced resectable gastroesophageal adenocarcinoma

Trial Identifier: D9804C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: July 2025
Primary Completion Date: December 2026
Study Completion Date: September 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H4A 3J1
CA, QC Montreal, QC, CA, H2X 3E4
CN Chengdu, CN, 610041
CN Fuzhou, CN, 350014
CN Hangzhou, CN, 310003
ES Barcelona, ES, 08035
ES Barcelona, ES, 08036
ES Elche, ES, 03203
ES Málaga, ES, 29010
ES Orense, ES, 32005
ES Oviedo, ES, 33011
ES Santander, ES, 39008
ES Valencia, ES, 46010
GB Headington, GB, OX3 7LJ
GE Tbilisi, GE, 0144
GE Tbilisi, GE, 0112
GE Tbilisi, GE, 0114
GE Tbilisi, GE, 0177
IT Milano, IT, 20133
IT Milano, IT, 20162
IT Rozzano, IT, 20089
IT Udine, IT, 33100
IT Vicenza, IT, 36100
JP Chuo-ku, JP, 104-0045
JP Fukuoka-Shi, JP, 812-8582
JP Hidaka-shi, JP, 350-1298
JP Kitaadachi-gun, JP, 362-0806
JP Nagoya-shi, JP, 464-8681
JP Osaka-shi, JP, 541-8567
TR Erzurum, TR, 25240
TR Fatih-Istanbul, TR, 34098
TW Taipei, TW, 11217
TW Taoyuan City, TW, 33305
US, DC Washington, DC, US, 20007
US, DE Newark, DE, US, 19713
US, MI North Shores, MI, US, 49444
US, NY New York, NY, US, 10065
US, NY New York, NY, US, 10032